Burns and Biofilms: Priority pathogens and in vivo models

Copyright © 2021 The Author(s). Burn wounds can create significant damage to human skin, compromising one of the key barriers to infection. The leading cause of death among burn wound patients is infection. Even in the patients that survive, infections can be notoriously difficult to treat and can cause lasting damage, with delayed healing and prolonged hospital stays. Biofilm formation in the burn wound site is a major contributing factor to the failure of burn treatment regimens and mortality as a result of burn wound infection. Bacteria forming a biofilm or a bacterial community encased in a polysaccharide matrix are more resistant to disinfection, the rigors of the host immune system, and critically, more tolerant to antibiotics. Burn wound-associated biofilms are also thought to act as a launchpad for bacteria to establish deeper, systemic infection and ultimately bacteremia and sepsis. In this review, we discuss some of the leading burn wound pathogens and outline how they regulate biofilm formation in the burn wound microenvironment. We also discuss the new and emerging models that are available to study burn wound biofilm formation in vivo.British Society for Antimicrobial Chemotherapy BSAC-2018-0095; Innovate UK Smart Grant 37800, FRAME, Young European Research University Network Mobility Award, NC3Rs PhD Studentship NC/V001582/1; BBSRC New Investigator Award BB/V007823/1; Academy of Medical Sciences; Wellcome Trust; UK Government Department of Business, Energy and Industrial Strategy; British Heart Foundation/Diabetes UK Springboard Award [SBF006\1040]

Carbon source competition within the wound microenvironment can significantly influence infection progression.

......RRMC is supported by the British Society for Antimicrobial Chemotherapy BSAC-2018-0095. RRMC and EM are supported by the NC3Rs PhD Studentship NC/V001582/1. RRMC is supported by a Biotechnology and Biological Sciences Research Council New Investigator Award BB/V007823/1 and Medical Research Council Grant MR/Y001354/1. RRMC is also supported by the Academy of Medical Sciences/the Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/the British Heart Foundation/Diabetes UK Springboard Award [SBF006\1040]